ad image

Portable CMC

1 / 1
Revolutionary CDMO Wheeler Bio Appoints Patrick Lucy as CEO
CDMO

Revolutionary CDMO Wheeler Bio Appoints Patrick Lucy as CEO

David Alvaro, Ph.D.

Pharma's Almanac

PAO-10-24-CL-08Oct 11, 2024
Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform
Leap-In Transposase

Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform

Wheeler Bio

PAO-06-24-CL-05May 30, 2024
How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success
The PHASE Platform

How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success

Wheeler Bio

PAO-05-24-CL-01May 08, 2024
Wheeler Bio
Portable CMC

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Wheeler Bio

PR-M02-29-01Feb 29, 2024
Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform
CMC

Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform

Wheeler Bio

PAO-12-23-CL-04Feb 08, 2024
Wheeler Bio

Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC

Wheeler Bio

PR-M11-23-01Nov 08, 2023
Wheeler Bio

Wheeler Bio Announces Grand Opening of Biomanufacturing Facility

Wheeler Bio

PR-M10-23-01Oct 05, 2023
Wheeler Bio
Business Leadership

Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Officer

Wheeler Bio

PR-M08-23-01Aug 15, 2023
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
CMC

The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies

Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.

Wheeler Bio

PAO-07-23-CL-05Jul 26, 2023
Wheeler Bio
Leadership

Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer

Wheeler Bio

PR-M06-23-02Jun 06, 2023
Wheeler Bio
Series A Funding

Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma

Wheeler Bio

PR-M10-22-02Oct 05, 2022
Integrating Cell Line and CMC Development
Cell Line Development

Integrating Cell Line and CMC Development

Stephen Hamilton, Ph.D.; Mike Brem

Wheeler Bio

PAO-06-022-CL-12Sep 02, 2022
Wheeler Bio
Financing

Wheeler Bio Announces $14M Seed Round To Expand Access To Portable CMC™

Wheeler Bio

PR-M01-22-01Jan 04, 2022
1 / 1